Download Files:
Products Details
Product Description
– ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase[1].
Web ID
– HY-156285
Shipping
– Room temperature
Molecular Formula
– C25H29N5O3
References
– [1]Qiangsheng Zhang, et al. Discovery of novel G9a/GLP covalent inhibitors for the treatment of triple-negative breast cancer. Eur J Med Chem. 2023 Sep 28:261:115841.
Molecular Weight
– 447.53
SMILES
– C=CC(NC1=CC(C2=NC3=CC(OC)=C(C=C3C(NC4CCN(CC4)C)=N2)OC)=CC=C1)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– 10 mM in DMSO
Target
– Apoptosis;Histone Methyltransferase
Isoform
– EHMT1/GLP/KMT1D;EHMT2/G9a/KMT1C
Pathway
– Apoptosis;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
